

Sponsors:



Supporting Partners:



Media Partners:



Mar 14|15  
**2019**  
Berlin | Germany



**12<sup>th</sup> Berlin Conference on Life Sciences**

# Novel Antimicrobials and AMR Diagnostics 2019

**amr-conference.com**  
**#AMRconference**

We are part of the  
**#GlobalAMRChallenge**

Organisation: BIOCOM AG | Lützowstraße 33-36 | 10785 Berlin | Germany  
Katja Boelcker | amr@biocom.de | Tel. +49 (0)30 264921-51

**BIOCOM**



**Network:** AMRconference  
**Password:** AMR-2019

# More collaboration needed:

## How to efficiently finance AMR innovation?

Developing new therapies and diagnostics to fight antimicrobial resistance in human and animal health is becoming more important than ever. However, financing AMR innovation still is a critical issue. Whereas many big pharma companies have left the field, other stakeholders are stepping in. Different initiatives on the international, European and national level – be it as private action or public-private undertaking – are currently underway to improve the environment for researchers and developers from science and business. Awareness on the policy level has significantly increased as well, and many stakeholders expect that 2019 will offer a critical turning point in ongoing discussions about push and pull incentives.

This year's #AMRconference is particularly focusing on the challenges for small and medium-sized therapeutic and diagnostics companies active in this field. Taking place for the third time, the “Novel Antimicrobials and Diagnostics 2019” conference organised by BIOCOM together with the support of BEAM Alliance and many others will offer a platform for joint discussions, networking and bridging the gaps. Enjoy the in-depth insights of more than 70 top-class speakers from all over the world! We are pleased to welcome you for these two conference days full of intensive talks in Berlin.

The BIOCOM Team



**Novel Antimicrobials  
and AMR Diagnostics**

**14–15 March 2019**  
Berlin | Germany

“BIOCOM AG will connect enterprises in Europe to pharmaceutical companies, academia, investors and governmental institutions through its annual **Novel Antimicrobials and Antimicrobial Resistance (AMR) Diagnostics** conference occurring in Berlin in March 2019. This will help enterprises to discuss specific challenges in bringing new drugs to the market.”

We are part of the  
**#GlobalAMRChallenge**

# BIOCOM

unparalleled in life science communication



*For more than three decades, Berlin-based BIOCUM has offered professional communication expertise and a wide range of specialist media for the life sciences. For us, scientific excellence goes hand in hand with sound communication – either as a double qualification offered by our individual employees or combined together in project teams. Based on in-depth knowledge of the most recent developments within the life sciences research and business community, we produce high-quality media products and offer targeted services to different clients in the private and public sector.*

## Journals and books:

Since 1986, BIOCUM AG has been publishing German and English specialist journals and books on biotechnology, life sciences and medical technology – an indispensable resource for our readers and advertising customers.

## Corporate media:

We provide tailored communication to specific target groups – be it individual articles, high-quality brochures, leaflets and catalogues, regular customer magazines, internet portals, or social media campaigns and much more.

## Events and exhibitions:

With professional expertise and an extensive network in the fields of biotechnology, bioeconomy and medical technology, we plan and implement tailor-made in-house and commissioned events in Europe.

## EU project communication:

Early in the application phase, we join R&D consortia as a member and assume responsibility for the “Communication and Dissemination” work package.

## Reports and statistics:

We carry out high value market and technology studies. Depending on requirements, we conduct qualitative and quantitative surveys and compile research data and facts. The results are clear, meaningful reports with high-quality and reliable information.

## Video production:

The highest quality from research, shooting and editing to video distribution. Online magazines, explanatory films, documentaries, and event videos: we produce sophisticated films under one roof.

**Interested in learning more? Please don't hesitate to contact us.**  
**[www.biocom.de](http://www.biocom.de)**



# BEAM Alliance:

One voice for European SMEs working in the AMR space.

Since its inception in 2016, the BEAM Alliance has succeeded in uniting European Small Medium Enterprises (SMEs) working in the field of AMR. The BEAM Alliance enables innovation in AMR research by giving its members a unique voice to propose and support policies and incentives that enable much needed progress in the discovery and development of novel antibacterial therapies and diagnostics in Europe. Collaborating with the existing community of global stakeholders, BEAM Alliance aims at the implementation of tangible solutions that support SMEs as the driving force of today's innovation in the field, by recommending bold incentives that warrant action by policymakers to stimulate sustainable innovation.

For most stakeholders in the field of AMR (including governments, patients, industry representatives and other policy makers), BEAM is now recognised as a unique contributor to help our understanding of the complex array of cross-disciplinary issues mixing science, finance and policymaking. In Europe, BEAM has established channels of communication with the European Commission and national Governments, politicians and international, national and local policy makers. At a global level BEAM participates in international science and policy forums to understand and influence activities that can support the needs of its members and the challenges in developing solutions to fight AMR. Through its efforts BEAM offers SMEs the means to directly influence debate and policy making locally, nationally and internationally.

## **A roadmap to turn stakeholders' declarations into concrete actions**

A significant BEAM strategic action has been to propose a categorization of antimicrobial features from a patient-need perspective. Last year details of each of the BEAM members technological assets dedicated to fighting AMR were collated into a comprehensive pipeline document which demonstrated that together BEAM members are investing in a broad diversity of prevention and therapeutic strategies to fight AMR. Another strategic action of BEAM planned for the coming year is to strengthen its capacity to advo-



cate for a better inclusion of diagnosis as part of the global AMR solution. In that regard, a dedicated task force is being built to support this work. The task force will approach the issues in a broad-minded way. Should anyone be interested to support this activity please contact us.

Recently significant progress has been made to implement different PUSH financial incentives. In particular the CARB-X and BARDA initiatives are extremely effective, primarily because they deliver non-dilutive, non-consortium based funding and operate in such a way that they complement the usual way companies develop their products. The desire of CARB-X to create different European accelerators recognizes the important role that European innovation plays in combatting AMR and is enthusiastically welcomed by the BEAM Alliance. In addition the upcoming EU Horizon Europe framework programme represents a good opportunity to design relevant SME-funding instruments. BEAM is releasing a document, detailing its recommendations as to how such financial incentives should be structured to best suit the needs of its members, critical stakeholders in fighting AMR.

Last but not least, BEAM is strengthening its call to action to implement different PULL incentives. This includes urgently setting up pilot programs aimed at gaining practical knowledge on utility of the many proposed theoretical incentive models aimed at fixing the current AMR market failure. The recent announcement of UK's willingness to implement measures to explore new incentive approaches, such as de-linking the price paid for antimicrobials from the volumes sold, is a very positive first-step. BEAM is preparing a memo urging other governments and policy makers to follow the example set by the UK to start testing the viability and effectiveness of different PULL incentives. The implementation of appropriate PUSH and PULL financial incentives will be a crucial factor to enable industry to retain a focus on developing innovative AMR solutions.

**For more information, see:**  
**[www.beam-alliance.eu](http://www.beam-alliance.eu)**

# At a glance

## Pre-conference Programme

<b>13:00–14:30</b>	Pre-conference workshop (limited seats available) <b>Resistance testing – beyond serial passage experiments</b>  Jointly organised by Novo Repair Impact Fund, CARB-X, GARDP and Wellcome Trust	<b>Room Rubin</b> page <b>9</b>
<b>14:30–15:30</b>	Pre-conference meeting <b>BEAM Alliance General Assembly (for members only)</b>	<b>Room Turmalin</b> page <b>9</b>

## Day 1 14 March

## Conference Day 1


<b>15:00–19:30</b>	Registration, Poster Presentations and Exhibition open			
<b>16:00–17:45</b>	<b>Plenary Session</b> <b>Policy Session – Part I</b> <b>How to leverage public and private support to efficiently finance AMR innovation?</b> Co-organised with WHO and UNCTAD			
	<b>Room Saphir</b> page <b>10</b>			
<b>17:45–18:00</b>	Break, Exhibition and Poster Presentations			
<b>18:00–19:30</b>	<b>Parallel Sessions and Investor Partnering</b>			
	<b>Policy Session – Part II</b>	<b>Session 1</b>	<b>Session 2</b>	<b>Investor Partnering</b>
	<b>Workshop: How to set up a new AMR innovation fund?</b> Co-organised with WHO and UNCTAD	<b>Academic innovations</b> (AMR therapeutics and diagnostics)	<b>Non-traditional approaches and enabling technologies</b>	<b>Pre-scheduled 1-to-1 meetings</b> (18:00–20:00)
	<b>Room Saphir</b> page <b>11</b>	<b>Room Turmalin</b> page <b>12</b>	<b>Room Rubin</b> page <b>13</b>	<b>Room Aquamarin</b> p <b>9</b>
<b>19:30–21:30</b>	<b>Evening Reception</b> Location: Radisson Blu Hotel – Foyer Berliner Dom, 7 <sup>th</sup> Floor			
	page <b>8</b>			

## Conference Day 2

08:00–17:00	Registration, Poster Presentations and Exhibition open		
08:50–10:30	<b>Plenary Session</b>  <b>Update and progress report with regard to AMR innovations for human and animal health</b>  <b>Panel debate – too many cooks spoil the broth: Is the AMR field getting over-coordinated by public and private initiatives? What is really needed to drive innovation?</b>		
			Room Saphir page 16
10:30–11:00	Break, Exhibition and Poster Presentations		
11:00–12:30	<b>Parallel Sessions</b>		
	<b>Session 3</b>  Clinical development and regulation  Room Saphir page 17	<b>Session 4</b>  Market access – UK as a new international role model for novel incentives?  Room Rubin page 18	<b>Session 5</b>  Surveillance – a new tool to improve R&D for drugs and diagnostics, the challenge of data integration and the role of large industry/SMEs  Room Tumalin page 19
12:30–14:00	Lunch, Exhibition and Poster Presentations		
14:00–15:30	<b>Parallel Sessions and Investor Partnering</b>		
	<b>Session 6</b>  Therapeutics (humans)  Room Saphir page 20	<b>Session 7</b>  Diagnostics (humans)  Room Rubin page 21	<b>Session 8</b>  Animal health – synergies between human and animal health experts to fight AMR  Room Turmalin page 23
			<b>Investor Partnering</b>  Pre-scheduled 1-to-1 meetings (13:30–15:30)  Room Aquamarin p 9
15:30–16:00	Break, Exhibition and Poster Presentations		
16:00–17:35	<b>Plenary Session</b>  <b>Financing Session</b>  Start-up pitch and investor's talk		
			Room Saphir page 24
17:35–17:45	Poster Prize Ceremony		Room Saphir page 26
17:45–18:30	Closing Reception		Foyer

**Day 2**  
15 March

# Floorplan



**Microsynth**  
SEQLAB

**CDD.VAULT**  
Complexity Simplified™

**DZIF**  
German Center  
for Infection Research

**InfectoGnostics**  
Research Campus Jena

**HEMEX**

**GARDP**  
Global Antibiotic Research  
& Development Partnership

**A&M**  
LABOR FÜR ANALYTIK

**CARB-X**  
Combating Antibiotic Resistant Bacteria

**Resistell**

## Evening Reception

Time:

**14 March, 19:30–21:30**

Location:

Radisson Blu Hotel – Foyer Berliner Dom, 7th Floor  
(use elevator from the main hotel foyer)

Please note:

Only for conference delegates who have registered  
for the evening reception.

Sponsored by **sphingotec**

# Pre-conference

## Room Rubin

13:00–14:30

Pre-conference Workshop (limited seats available)

### Resistance testing – beyond serial pass experiments

Jointly organised by Novo Repair Impact Fund, CARB-X, GARDP and Wellcome Trust



Emergence of mutational resistance - threat or myth?

**Ursula Theuretzbacher**

Founder, Center for Anti-Infective Agents (CEFAIA), AT



Testing of dual/multiple target drugs

**Michael Mourez**

Head of Bacteriology/Omics Platform, Evotec ID Lyon, FR



Testing of single target drugs

**Diarmaid Hughes**

Professor of Medical Molecular Bacteriology, Uppsala University & ENABLE, SE

**Day 1**  
14 March

13:00–14:30

14:30–15:30

## Room Turmalin

14:30–15:30

Pre-conference Meeting

### BEAM Alliance General Assembly (for members only)

# Investor Partnering

Delegates of the #AMRconference have the opportunity to pitch their business / collaboration idea, technology or R&D project to AMR-relevant investors and public funders in one-to-one meetings.

Note, the application and selection process already took place prior to the conference. All participating companies have been informed about the status of their application and meeting requests with investors of their choice.

### The pre-scheduled one-to-one meetings take place as follows:

Day 1, 14 March: 18:00–20:00

Day 2, 15 March: 13:30–15:30

The length of each meeting slot is 15 minutes (10 mins meeting time + 5 mins break).

Please check your individual meeting schedule for times and locations of your confirmed meetings.

### Meeting locations:

Rooms Aquamarin, Topas, Opal

Need help? Please see the Partnering Help Desk in front of Room Aquamarin.

See [page 36](#) for a list of participating investors and public funders.

# Plenary Session

## Policy Session – Part I

Room Saphir

16:00–17:45

### How to leverage public and private support to efficiently finance AMR innovation?

Co-organised with WHO and UNCTAD

The Policy Session will be organised together with WHO/UNCTAD and will serve as a follow-up of the AMR session at the World Investment Forum in October 2018. After introductory presentations a panel debate will discuss major challenges of setting up a new AMR investment fund.



#### Setting the scene: Challenges in AMR innovation

**Christoph Spennemann**

UNCTAD/United Nations Legal Officer and Officer-in-Charge,  
Intellectual Property Unit Geneva, CH (Moderation)



#### Push and pull: Where are we and will we achieve a sustainable solution for the sector? – View from the EU SME perspective

**Marc Gitzinger**

CEO, BioVersys AG, CH



#### Fostering the development of antibacterial treatments – What WHO can do

**Peter Beyer**


Senior Advisor Department of Essential Medicines & Health Products,  
World Health Organization



#### Changing risk perceptions through the eyes of an accelerator in the ecosystem of ABR

**Christoph Riemann**

CEO, Global Investment Bridge AG und Bacteriobator, DE



#### Antimicrobial market dynamics – impact on investing

**Ruby Holder**


Vice President, Investments Roivant Pharma, US



#### Defining new trajectories for AMR innovation – a third-world perspective

**Anand Anandkumar**

Co-founder & CEO, Bugworks, IN



#### Push & pull incentives in the US and Europe – next steps

**Kevin Outterson**

Executive Director, CARB-X, US

#### Panel Debate with all speakers

16:40–17:45

Day 1  
14 March

16:00–17:45



# Parallel Session

## Policy Session – Part II

Room Saphir

18:00–19:30

### Workshop: How to set up a new global AMR innovation fund?

Co-organised with WHO and UNCTAD

The workshop will focus on a concept for a novel health care impact investment fund to finance the development of new antibacterial treatments and other means to prevent, diagnose and treat resistant infection. A financial model for such a fund will be presented to seek feedback from participants on the underlying assumptions and possible set up of the fund. The fund would focus on investment into innovative approaches to prevent or treat infections caused by resistant bacteria that are on the WHO's list of priority pathogens and complement the different existing R&D funding initiatives focusing on clinical phase II and III as well as new technologies to fight AMR for example in the area of IPC.



**Christoph Spennemann**

UNCTAD/United Nations Legal Officer and Officer-in-Charge,  
Intellectual Property Unit Geneva, CH (Chair and Moderation)



**Peter Beyer**

Senior Advisor Department of Essential Medicines & Health Products,  
World Health Organization (Chair)



**Christopher Egerton-Warburton**

Co-CEO, Lion's Head Global Partners, UK



**Victoria Goodfellow**

Executive Director, Lion's Head Global Partners, UK

**Day 1**  
14 March

18:00–19:30

# Parallel Session

## Session 1

Room Turmalin

18:00–19:30

### Academic innovations

The session will highlight application-oriented academic research on AMR therapeutics and diagnostics. It will be opened by an introduction that emphasizes the role of academia in product development.



**Mark Brönstrup**

Head of the Department Chemical Biology,  
Helmholtz Centre for Infection Research, DE (Chair & Moderation)



**Till Bachmann**

Deputy Head of Division of Infection and Pathway Medicine,  
University of Edinburgh, UK

18:00–18:15

### Antibiotic discovery from microbial natural products

18:15–18:30



**Olga Genilloud**

Scientific Director, Fundación MEDINA, ES

### Boosting innate immunity to treat pneumonia

18:30–18:45




**Jean-Claude Sirard**

Research Director, Institut Pasteur de Lille, Inserm, FR

### Applying the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify drug combinations that can overcome multi-drug-resistance

18:45–19:00



**Robin Michelet**

Post-doctoral researcher, Freie Universität Berlin, DE

### Lipoprotein synthesis as a target for new antibiotics

19:00–19:15



**Martin Caffrey**

Professor, Trinity College Dublin, IE

### Raman-dielectrophoresis chip for rapid antimicrobial susceptibility testing

19:15–19:30



**Richard Grohs**

MD student, Leibniz Institute of Photonic Technology,  
InfectoGnostics Research Campus, DE

**Day 1**  
14 March

18:00–19:30


## Session 2

## Room Rubin

18:00–19:30

### Non-traditional approaches and enabling technologies

The session will showcase therapeutic developments that go beyond traditional small molecule approaches as well as platform technologies that enables the discovery and development of new antibiotics, alternatives to antimicrobials, AMR therapies and diagnostic approaches.



**Ute Killger**

Partner, Boehmert & Boehmert, DE (Chair & Moderation)

18:00–18:10



#### Direct metabolic monitoring for AST and antibiotic drug development

18:10–18:20

**Magnus Jansson**

CSO, Symcel, SE



#### Treating infections by modulating innate immunity

18:20–18:30

**Egill Måsson**

CEO, Akthelia Pharmaceuticals, IS



#### crPhage: A recombinant phage platform based on CRISPR-Cas3 to address AMR and diseases of the microbiome

18:30–18:40

**Dave Ousterout**

CTO, Locus Biosciences, Inc., US



#### AMR as a big data challenge: AI-powered DNA testing for precision medicine in infectious diseases

18:50–19:00

**Achim Plum**

Managing Director, Ares Genetics, AT & CBO, Curetis N.V., DE



#### Leveraging immunotherapy to address infectious disease

19:00–19:10

**Jennifer R Schneider**

VP Business Development, Centauri Therapeutics Ltd, UK



#### Deal with messy AMR data the clever way

19:10–19:20

**Claus Stie Kallesøe**

CEO & Co-founder, grit42, DK



#### Solutions for collaborative drug discovery connecting researchers globally

19:20–19:30

**Susana Tomasio**

Senior Application Scientist, CDD Vault, UK

**Day 1**  
14 March

18:00–19:30

A microscopic view of several bacteria, likely E. coli, showing their characteristic rod shape and internal structure. The bacteria are stained, with a pinkish-red outer layer and a darker, blueish-purple core. They are scattered across the frame, some in focus and others slightly blurred, creating a sense of depth.

# The UK: your partner for developing and commercialising solutions for antimicrobial resistance

*From the discovery of Penicillin to the development of rapid point-of-care tests and genomic screening, the UK has always led the world in trying to better understand, detect, diagnose, treat, and control infectious diseases and the growing challenge of antimicrobial resistance (AMR).*

*We offer cutting-edge research and talent, established platforms for innovation and clinical trials, support for technology development and informatics capabilities, world-renowned public health and regulatory expertise and global standards, a culture of collaboration with access to partners, and a launch-pad to global markets for prevention, diagnosis, treatment and disease management.*

*This is underpinned by a national action plan alongside our 20-year vision to tackle AMR, in which resistance is effectively contained and controlled across human health, animal health, the food chain and environment communities.*

*Find further information on the action plan and vision on [www.gov.uk](http://www.gov.uk).*

## Why select the UK for developing antimicrobial resistance solutions?

- A world class research base, cluster, and talent pool.
- **Global leadership:** A new 20-year vision and 5-year national action plan on AMR, launched in January 2019, builds upon the achievements of the UK's 5-year AMR strategy (2013 to 2018) and sets out the next steps for the UK's vision for AMR in 2040. Targets include cutting the number of drug-resistant infections; reducing antibiotic use and infection prevention. This will be supported by data harvested by new technology and a value based approach to medicines. The plans cover animals and the environment as well as human health.
- **Financial commitment to research:** The UK Government will build on its investment in AMR R&D in the coming years. It recently funded over £64m of AMR-related projects through the National Institute for Health Research and Research Council programmes. Other schemes encouraging international research collaboration include the £1bn Ross Fund to tackle malaria and infectious diseases; the £1.5bn Global Challenges Research Fund, the Fleming and Newton Funds, and the Global Antimicrobial Resistance Innovation Fund.
- **A clinical trial and testbed platform through the National Health Service (NHS):** The NHS is the world's largest integrated healthcare system, treating more than 60 million people, with over £1bn annual investment in a national platform for clinical research and study support service for sponsors and CROs.
- **A strong industry cluster** covering discovery and development of vaccines, therapeutics, diagnostics, informatics and One Health approaches (encompassing human and animal health), and a strong Clinical Research Organisation base.



## National infrastructure for treatment, diagnostic and AMR systems research and development

- **The AMR Centre** based at Alderley Park in Cheshire is a joint private-public initiative to support and accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept.
- **Public Health England** has established a centralised whole genome sequencing service, transforming a national bacteriology reference laboratory into a genomics-led service. Pathogen genomics is a powerful approach to investigate and manage infectious diseases.
- The UK is investing up to £66m in capital funding to build and establish a good manufacturing practice (GMP)-capable **UK National Vaccines Development and Manufacturing Centre**.
- **Wellcome Trust**, one of the world's leading funders of biomedical R&D, supports global efforts in antimicrobial resistance through co-funding of the CARB-X scheme.
- **Two National Institute for Health Research (NIHR) Health Protection research Units** are focused on Healthcare Associated Infections (HCAIs) and AMR, leading on research to support the development of effective approaches to combat AMR. Also part of the NIHR, **four Biomedical Research Centres** (in Cambridge, Oxford and two in London linked to Imperial and University College London Hospitals) conduct translational research to transform scientific breakthroughs into life-saving treatments for patients.

## Reducing the risks and creating an efficient route to product development

- More than 150 companies working on infection management and treatment have benefited from funding of over £58m over the last 10 years through **Innovate UK**, the UK's national innovation agency, with a focus on commercial translation.
- The **Medicines Discovery Catapult** based at Alderley Park will focus on medicines; diagnostics; biomarkers; and early-stage clinical trial support. The Catapult will serve as a community one-stop shop for all drug-based approaches.
- **NIHR In vitro Diagnostics Co-operatives** in London, Leeds Newcastle and Oxford, support companies developing the evidence and evaluating diagnostics to support commercialisation.
- The **MHRA Innovation Office**, offering a single point of access for all innovative medicines and medical devices, is a key resource for all developers in the personalised medicine area.
- The **Early Access to Medicines Scheme** makes promising new unlicensed medicines available to UK patients at an earlier stage, especially in areas of high unmet clinical need.

The UK's Department for International Trade (DIT) is the specialist Government department that:

- helps UK-based companies access overseas markets, providing confidential advice and support necessary to assist you in achieving your export goals.
- helps overseas companies bring their high-level investment to the UK, providing professional, personalised and practical assistance and advice.

These services are offered through DIT's extensive network of sector and market specialists both in the UK and in British embassies and diplomatic offices around the world.

For further information please contact:

**Laurie Williams**

**Senior Business Development Manager**

Tel: +49 (0)211 944 8 276

Email: [Laurie.Williams@mobile.trade.gov.uk](mailto:Laurie.Williams@mobile.trade.gov.uk)

Please follow us on Twitter @trade.gov.uk

[www.great.gov.uk](http://www.great.gov.uk)

## 10 million deaths

Number of deaths annually by 2050 if AMR isn't addressed

## \$100 trillion

Estimated lost economic output due to AMR



# Plenary Session

## Plenary Session

## Room Saphir

8:50–10:30

### Update and progress report with regard to AMR innovations for human and animal health

The plenary session will give a progress report on AMR innovations and financing in the therapeutics and diagnostics field. It will have a one health approach, covering human health and animal health aspects. A focus will be on developments relevant for SMEs and mid-size companies. It will address their needs and day-to-day challenges and will open the room for solutions that will be presented and discussed throughout the day.



**John H. Rex**

CMO, F2G Ltd. Expert-in-Residence, Wellcome Trust, US (Chair & Moderation)

8:50–8:55



### Priority setting: analyzing the development pipeline and developing target product profiles for missing products

**Peter Beyer**

Senior Advisor Department of Essential Medicines & Health Products, World Health Organization

8:55–9:10



### Observations from REPAIR's 1st year

**Aleks Engel**

Partner, Novo Seeds & Director, Novo Holdings, REPAIR Impact Fund, DK

9:10–9:25



### Innovation and challenges around rapid antimicrobial susceptibility testing

**Alex van Belkum**

R&D Director, bioMérieux, FR


9:25–9:40

**Panel Debate:** Too many cooks spoil the broth: Is the AMR field getting over-coordinated by public and private initiatives? What is really needed to drive innovation?

9:40–10:30



**Elmar Nimmesgern**  
Global AMR R&D Hub  
Secretariat Lead, DE



**Jonathan Pearce**  
JPI AMR & Medical  
Research Council, UK



**Cuong Vuong**  
Director Bacteriology  
AiCuris GmbH, DE



**Michael Mourez**  
Head of Bacteriology/Omics  
Platform, Evotec ID Lyon, FR

**Day 2**  
15 March

8:50–10:30



## Session 3

## Room Saphir

11:00–12:30

### Clinical Development & Regulation

The focus of session 3 will be on the challenges which come along with clinical development of new antimicrobials thereby having a focus on trial design for non-traditional routes and the need for new guidelines, the value of clinical trial networks and measures in preclinical development that could reduce attrition in clinical phases. The session will be complemented by case studies from clinical stage SMEs & a panel debate.

#### Part 1



**Helmut Kessmann**

Head Business Development, Polyphor Ltd, CH (Chair & Moderation)



#### Development of pathogen specific antibiotics: challenges and opportunities

11:00–11:15

**Glenn Dale**

Chief Development Officer, BioVersys, CH



#### Trial design and execution for non-traditional innovative products: Sharing the experience of a European clinical trial network (COMBACTE)

11:15–11:25

**Florence Séjourné**

CEO of Da Volterra, President of the BEAM Alliance, FR



#### Development of EBL-1003 (apramycin) for therapeutic use in humans (case study from ENABLE)

11:25–11:30

**Sven Hobbie**

CEO, Juvabio AG, CH



#### Public health driven antibiotic development: Initial challenges and opportunities

11:30–11:40

**Seamus O'Brien**

R&D Director, Global Antibiotic Research and Development Partnership (GARDP), CH

#### Part 2


11:40–12:30

#### Q&A Session: "Regulatory pathways for traditional and non-traditional antibacterial therapies"



**Karen Gallant (Moderation)**

Global R&D Director, CARB-X, US



**Edward Cox**

Director, Office of Antimicrobial Products CDER, FDA, US



**Sumathi Nambiar**

Director, Division of Anti-Infective Products (DAIP), Office of Antimicrobial Products CDER, FDA, US

**Day 2**  
15 March

11:00–12:30

# Parallel Session

## Session 4

Room Rubin

11:00–12:30

### Market Access – UK as a new international role model for novel incentives?

The session will discuss one of the major topics in the AMR community: the broken economic model. It will focus on current instruments available to incentivise AMR innovation and looks at new PUSH and PULL strategies proposed by experts. The new de-linked payment model proposed by the UK government in January 2019 will be among the topics discussed: Could it be a role model for other national governments?

A panel will shed light on the SMEs perspective: what are their needs with regard to reimbursement and return of investment and which instrument would fit the best to support growing the community and how much coordination on the global level is needed?



**Elmar Nimmesgern**

Secretariat Lead, Global AMR R&D Hub, DE (Chair & Moderation)

11:00–11:05



### Journey towards new value assessment of antimicrobials and delinked payment in the UK

**Colm Leonard**

Consultant Clinical Adviser, National Institute for Health and Care Excellence, UK Consultant Thoracic Physician/Honorary Clinical Senior Lecturer, University of Manchester, UK

11:05–11:20



### Global progress towards sustainable antibiotic R&D

**Jeremy Knox**

Policy Lead, Drug-resistant infections, Wellcome Trust, UK

11:20–11:30



### Have we turned all stones yet?

**Marie Petit**

Coordinator, BEAM Alliance & Principal, Villiger Valuation, FR

11:30–11:40



### Economic incentives for the development of new antibiotics. Recommendations for Sweden

**Enrico Baraldi**

Professor, Uppsala University, SE

11:40–11:50



### Novel diagnostics – AMR Quick Fix (if we fix the economics)

**Achim Plum**

Managing Director, Ares Genetics, AT & CBO, Curetis N.V., DE

11:50–12:00

### Panel Debate with all speakers

12:00–12:30

Day 2  
15 March

11:00–12:30

# Parallel Session

## Session 5

## Room Tumalin

11:00–12:30

### Surveillance – A new tool to improve R&D for drugs and diagnostics, the challenge of data integration and the role of large industry/SMEs

The session will have a special focus on how surveillance data can be used to create a more efficient, reliable and successful drug and diagnostic development process to combat antibiotic resistance in the long-term. It will present current strategies and international efforts of sharing and collecting existing data and will discuss the role of industry and SMEs within this challenge. Another aspect will cover the challenges to integrate human and animal health data and the related challenge to identify relevant diagnostic tools.



#### Drug resistant infections priority programme - transforming our response to drug resistant infections

**Ghada Zoubiane**

Science Lead of the Drug Resistant Infection Program, Wellcome Trust, UK  
(Chair & Moderation)

11:00–11:15



#### Importance of antibiotic surveillance data and Survey of Antibiotic Resistance (SOAR)

**Didem Torumkune**

Scientific Director - Global SOAR Lead Infectious Diseases, GlaxoSmithKline, UK

11:15–11:30



#### How hospital surveillance data can help measure AMR burden, identify trends and understand patient populations

**Adam Zerda**

Director, AMR Strategy and Development, Becton, Dickinson & Co, US

11:30–11:45



#### Surveillance in AMR: Lessons from the Pandemic Emergency Facility

**Manuel Villegas Caballero**

Senior Risk Modeller, Swiss Re, CH

11:45–11:55



**Clive Mason**

Senior Director, Anti-Infectives Research Summit Therapeutics & Member of the BEAM Alliance, UK

11:55–12:00

#### Panel Debate with all speakers

12:00–12:30

**Day 2**  
15 March

11:00–12:30

## Session 6

## Room Saphir

### 14:00–15:30 Therapeutics (humans)

This session will focus on innovative SMEs with new therapeutic approaches based on small molecules or peptides to directly target resistant bacteria. The session will be jointly moderated by BEAM Alliance and CARB-X.



#### The CARB-X approach to fostering innovative products

14:00–14:10

**Richard Lawson**

Director of Post-Award Support, CARB-X, US (Moderation)



#### BioVersys: Lifesaving medicines – during resistant times

14:10–14:20

**Marc Gitzinger**

CEO, BioVersys AG, CH & Vice President Board, BEAM Alliance (Moderation)



#### Antabio: novel antibacterials targeting critical priority MDR-GN pathogens

14:20–14:30

**Marc Lemonnier**

CEO, Antabio SAS, FR



#### Aelin therapeutics, using the power of aggregation to develop novel therapeutics

14:30–14:40

**Els Beirnaert**

CEO, Aelin Therapeutics NV, BE



#### A novel small molecule antibiotic for the treatment of Neisseria gonorrhoeae

14:40–14:50

**Paul Meo**

Associate Director, Anti-Infectives Research, Summit Therapeutics plc, UK



#### Precision medicine DNA-based antibiotics

14:50–15:00

**Andrew Lightfoot**

CEO, Procarta Biosystems, UK

#### Panel Debate with all speakers:

15:00–15:30

Which of the therapeutic approaches are the most promising to fight AMR and which hurdles from a technology point of view do exist?

**Day 2**  
15 March

14:00–15:30

# Parallel Session

## Session 7

Room Rubin

14:00–15:30

### Diagnostics (humans)

This session will focus on the relevance of diagnostics in the fight against antimicrobial resistance and provides an overview of the most recent developments in this area. Speakers from different companies will highlight new diagnostic tests or panels for either susceptibility, point-of-care or point-of-prescription testing.



**Till Bachmann**

Deputy Head of Division of Infection and Pathway Medicine,  
University of Edinburgh, UK (Chair & Moderation)



**A new sample preparation and detection technology for infectious disease management at the point of care**

14:00–14:10

**Iain D. Miller**

CEO, SAW Dx, UK



**SensDx - rapid low cost and highly precise digital diagnostic device for identification biomarkers in biological samples**

14:10–14:20

**Katazyna Pala**

Business Development Director, SensDx SA, PL



**Resistell's rapid, phenotypic antibiotic susceptibility test**

14:20–14:30

**Danuta Cichocka**

CEO, Resistell, CH



**QuickMIC: Next-generation rapid AST from positive blood cultures with near point-of-care application**

14:30–14:40

**Christer Malmberg**

Lead Development Engineer, Gradientech AB, SE



**Go beyond detection – enabling resistance guided therapy for infectious diseases**

14:40–14:50

**Colin Denver**

CEO, Speedx, AU



**The AMR Diagnostics Accelerator**

14:50–15:00

**Cecilia Ferreyra**

Medical Officer, FIND & Diagnostic Use Accelerator, CH

### Panel Debate with all speakers:

Which are the major challenges to advance new diagnostics into the market?

15:00–15:30

**Day 2**  
15 March

14:00–15:30

# Flanders: from idea to market

Flanders, a region comprising the northern half of Belgium, might be small in surface area, but it's home to one of the most vibrant life sciences ecosystems in the world. And for good reason; Flanders' strategic location, vivid network of global life sciences players, excellent supportive incentives and talented workforce make it 'the place to be' to thrive in any life sciences subsector.

#2  
in Europe  
for number of  
clinical trials  
per capita

## Flanders' R&D-friendly tax system

**Innovation income deduction**  
up to **85%** of net innovation incomes  
exempt from corporate taxation

**R&D payroll tax incentive**  
recover up to **80%** of the withholding tax  
on professional income for researchers

**R&D investment deduction**  
**13.5%** of the investment value (at once)  
**20.5%** of the annual depreciation  
(staggered)



Fastest  
clinical approval  
in EU  
(15 days)



5%  
of global  
pharma output  
is developed  
here.

## Did you know that researchers from Flanders...

...were the first to unravel the DNA  
sequence of a gene?


...developed pioneering pharmaceuticals

...were the first to use stem cells in  
bone marrow transplants?

...created a lab-on-a-chip for  
early breast cancer  
discovery?



Belgium/  
Flanders ranks  
#1 for industrial-  
academic  
linkages<sup>4</sup>



## Connect with Flanders Investment & Trade

Flanders Investment & Trade (FIT) is your source of expertise regarding every aspect of doing business in Flanders. This governmental organisation provides comprehensive support for companies seeking to invest in and source from Flanders via its 90 offices worldwide. In addition to its broad network of stakeholders, working with FIT brings companies the benefits of tailored data, business-relevant insights and expert advice tailored to their unique situation.

In partnership with VIB, VLAIO and FlandersBio, Flanders Investment & Trade offers the services of a skilled **life sciences welcome team** dedicated to providing support and guidance to foreign life sciences and biotechnology investors in Flanders.

Flanders Investment & Trade - Berlin

berlin@fitagency.com | [www.investinlanders.com](http://www.investinlanders.com) | @Flandern\_DE | @InvestFlanders



# Parallel Session

## Session 8

## Room Turmalin

14:00–15:30

### Animal Health

To address the one health approach in tackling spreading antimicrobial resistance and the growing need for alternatives to antibiotics, session 8 will present therapeutic and diagnostic innovations in animal health showcasing new antimicrobial approaches and innovative AMR diagnostics for usage in veterinary settings. The session particularly aims at providing insights into possible synergies between human and animal health experts to fight AMR.



#### ICARS- a new AMR centre focusing on implementation research

14:00–14:10

**Robert Skov**

Lead of ICARS Project Team, National AMR coordinator,  
Statens Serum Institut, Copenhagen, DK (Chair & Moderation)



#### Preventive healthcare for more sustainable antibiotic use in animal health

14:10–14:20

**Sven Arnouts**

Business Development Manager, PROVAXS – Ghent University, BE



#### Using autogenous vaccines to control bacterial infections and reduce antibiotic treatments in livestock

14:20–14:30

**Dagmar Köhler-Repp**

Managing Director, RIPAC-LABOR GmbH, DE



#### Peptide targets for development of a new serological Q fever diagnostic test in ruminants

14:30–14:40

**Katja Mertens-Scholz**

Senior Scientist, Friedrich-Loeffler-Institut, DE



#### Artilysin® – the ingenious way to control bacteria

14:40–14:50

**Martin Griebel**

CEO, Lisando GmbH, DE



#### Swinging a double-edged sword

14:50–15:00

**Mikkel Bender**

CFO, BKG Vet Pharma, DK

#### Panel Debate: How can the animal health sector profit from the human health area?

15:00–15:30



**Gwynneth Thomas**  
Investment Manager,  
Stonehaven Incubate AG,  
UK



**Robert Leo Skov**  
Project Leader, International  
Centre for Antimicrobial  
Resistance Solutions, DK

**Day 2**  
15 March

14:00–15:30

## Financing Session

## Room Saphir

16:00–17:00 **Start-up Pitch**



**Peter Jackson**

Executive Director, AMR Centre Ltd, UK (Chair & Moderation)




**Pierre Tangermann**

Managing Director, PerioTrap Pharmaceuticals GmbH, DE



**Franziska Mandl**

Project Head aBACTER, Technical University Munich, DE



**Timothy Schulz-Utermoehl**

Co-founder and Director, Pedanius Therapeutics, UK




**Piotr Garstecki**

Board Member, Bacteromic sp. z o.o., PL



**Paul Ko Ferrigno**

CEO, metaLinear Ltd, UK




**Matthew Cummings**

Co-founder, CC Bio, UK



**Mathew Upton**

CSO, Amprologix, UK



**Özden Baltekin**

Founder & CSO, Astrego Diagnostics AB, SE



**Charlotte Bermingham,**

CTO, Vitamica Ltd, UK



**Coen Breedveld**

Co-founder, Levels Diagnostics, NL

## Jury




**Aleks Engel**

Partner, Novo Seeds & Director, Novo Holdings, REPAIR Impact Fund, DK



**Fiona Marston**

Director, Center of Excellence in Infectious Disease Research, UK



**Karen Gallant**

Global R&D Director, CARB-X, US




**Ruby Holder**

Vice President, Investments Roivant Pharma, US



**Peter Jackson**

Executive Director, AMR Centre Ltd, UK



**John Rex**

CMO, F2G Ltd. & Expert-in-Residence, Wellcome Trust, US

**Day 2**  
15 March

16:00–17:00

## Financing Session

## Room Saphir

### 17:00–17:30 Investor's Talk

The pitches will be ranked by a Jury of investors and representatives of funding initiatives from across the globe. The session will then be closed by a panel debate with representatives from private, public and corporate investors as well as by company representatives talking about their success of having raised private capital with AMR innovation in recent times.



**John Rex**  
CMO, F2G Ltd. & Expert-in-Residence,  
Wellcome Trust, US (Chair & Moderation)



**Aleks Engel**  
Partner, Novo Seeds & Director, Novo Holdings,  
REPAIR Impact Fund, DK



**Karen Gallant**  
Global R&D Director, CARB-X, US



**Ruby Holder**  
Vice President, Investments Roivant Pharma, US

### 17:30–17:35 Start-up Pitch Award Ceremony



**Peter Jackson**  
Executive Director, AMR Centre Ltd, UK (Moderation)



**Aleks Engel**  
Partner, Novo Seeds & Director, Novo Holdings,  
REPAIR Impact Fund, DK

**Day 2**  
15 March

16:00–17:30

# Poster Prize Ceremony




## Room Saphir

**17:35–17:45** The prize for the best poster will be announced at the end of the Financing Session.

### Jury



**Alex van Belkum**  
*R&D Director, bioMérieux, FR*



**John Rex**  
*CMO, F2G Ltd. & Expert-in-Residence, Wellcome Trust, US*



**Till Bachmann**  
*Deputy Head of Division of Infection and Pathway Medicine,  
University of Edinburgh, UK*



**Olga Genilloud**  
*Scientific Director, Fundación MEDINA, ES*



**Mark Brönstrup**  
*Head of the Department Chemical Biology,  
Helmholtz Centre for Infection Research, DE*

See the list of all posters on page 28–29.

**Day 2**  
15 March

17:30–17:45





# DIAGNOSTICS IS POWER

The power to sustain antibiotic efficacy  
for future generations

**#pioneeringdiagnostics**

Visit our dedicated website:

**[www.antimicrobial-resistance.biomerieux.com](http://www.antimicrobial-resistance.biomerieux.com)**



# Poster Exhibition

Poster No. 1–14 in the Foyer, Poster # 15–48 in Room Jade

No.	Title	Corresponding Author
<b>Therapeutics, Animal Health</b>		
1	Phage therapy against infections with antimicrobial drug resistant bacteria in farm and companion animals	Michael Böhringer, Friedrich-Loeffler-Institut, Jena, DE
<b>Therapeutics, Alternative Approaches</b>		
2	Influence of sodium salicylate on the pathogenicity of <i>Pseudomonas aeruginosa</i> under simulated wound fluid culture conditions	Erik Gerner, University of Gothenburg, Gothenburg, SE
3	Introducing the world's first sporicidal hand disinfectant generated in an in situ plasma process	Ansgar Schmidt-Bleker, Leibniz Institute for Plasma Science and Technology, Greifswald, DE
4	PeplDIS:Bioinformatics – Workflow combining pathogen surfome analyses with peptide high density microarray biodesigns and expressed chimeric proteins as exemplary life vaccines against a-typical pneumonia caused by Mycoplasmal infections	Hubert Bernauer, ATG:biosynthetics, Merzhausen, DE
5	Quorum sensing inhibition of multidrug resistant bacteria as a non-traditional approach to fighting AMR	Graham Dixon, Neem Biotech Ltd., Abertillery, UK
6	Novel peroxidase-mediated oral prodrug promises: Broad-spectrum site-selective inhibition of bacterial virulence and treatment of antibiotic resistant diarrhoeal illnesses.	Alexander Huang, Quellthera, Inc., San Carlos, US
7	3-D pharmacophores: access to novel antimicrobials and AMR diagnostics	Matthias S. Scholz, University of Bonn, Pharmaceutical Institute, Bonn, DE
8	Phages as antimicrobials – old tools revisited	Irene Huber, University of Hohenheim, Stuttgart, DE
<b>Therapeutics, Antimicrobial Peptide</b>		
9	OMN6 is a novel antimicrobial peptide targeting Gram-negative ESKAPE pathogens	Niv Bachnoff, Omnix Medical, Jerusalem, IL
10	Antimicrobial activity of newly designed antimicrobial peptides against multidrug-resistant bacteria belonging to the ESKAPE group.	Javier Moreno-Morales, Universitat de Barcelona, ISGlobal, Barcelona, ES
11	Biological evaluation of novel antibacterial peptide G346a with potent activity against drug-resistant bacterial pathogens	Jerzy Karczewski, Fraunhofer Center for Molecular Biotechnology, Newark, US
12	Plantaricin NC8 $\alpha\beta$ rapidly and efficiently kills <i>Staphylococcus</i> spp. and markedly enhances the effects of antibiotics	Hazem Khalaf, School of Medical Sciences, Örebro University, SE
13	Linear peptide antibiotics (LPAs) as an innovative approach to fighting antimicrobial resistance	Daniel Knappe, EnBiotix GmbH, Leipzig, DE
<b>Therapeutics, Antibiotics</b>		
14	Bacteriolytic enzyme ausresine – a new weapon against <i>Staphylococcus</i>	Izabela Sabala, International Institute of Molecular and Cell Biology, Warsaw, PL
15	Exemplification of the Discuva platform to identify novel small-molecule inhibitors of bacterial lipoprotein transport.	Clive Mason, Summit Therapeutics, Cambridge, UK
16	aBACTER – antimicrobial development	Franziska Mandl, Technical University of Munich, Munich, DE
17	Preclinical development of ANT2681, a specific inhibitor of bacterial metallo $\beta$ -lactamases (MBLs)	Marc Lemonnier, Antibio SAS, Labège, FR
18	Deletion of the <i>Pseudomonas aeruginosa</i> elastase (LasB) in Cystic Fibrosis isolate RP45 impairs establishment of chronicity in a mouse model of chronic infection	Marc Lemonnier, Antibio SAS, Labège, FR
19	Discovery of a novel diazabicyclooctane (DBO) bacterial serine $\beta$ -lactamase (SBL) inhibitor with broadened spectrum of activity against Gram negative multi-drug resistant pathogens	Marc Lemonnier, Antibio SAS, Labège, FR
20	Targeting antimicrobial resistance by blocking antibiotics efflux from Gram-negative bacteria	Björn Windshügel, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, DE
21	Pre-clinical development of Coralopyronin A – an antibiotic active against helminths, STIs and <i>Staphylococci</i>	Andrea Schiefer, University Hospital Bonn & German Center for Infection Research (DZIF), Bonn, DE
22	Disciformycins: A novel class of macrolide glycoside antibiotics from the <i>Myxobacterium pyxidicoccus fallax</i>	Frank Surup, Helmholtz Center for Infection Research & German Centre for Infection Research Association, Braunschweig, DE
23	Novel inverse agonists of <i>Pseudomonas aeruginosa</i> PqsR (MvfR) with potential for adjunctive therapy of chronic respiratory infections	Martin Empting, Helmholtz-Institute for Pharmaceutical Research Saarland & German Centre for Infection Research (DZIF), Saarbrücken, Germany
24	Repurposing of apramycin as a parenteral therapeutic for the treatment of Gram-negative systemic infections in humans	Sven N. Hobbie, Juvabis AG, Zurich, CH



## Poster No. 15–48 in Room Jade

No.	Title	Corresponding Author
25	Next generation sequencing for the research and development of novel antibiotics	Michael Mourez, Evotec ID Lyon, Marcy l'Etoile, FR
<b>Enabling Technology</b>		
26	Discovery and functional characterization of compounds that kill Gram-positive persister bacteria by a novel mechanism	Michael Mourez, Evotec ID Lyon, Marcy l'Etoile, FR
27	Access models for EU-OPENSOURCE ERIC	Katja Herzog, EU-OPENSOURCE ERIC, Berlin, DE
28	An in vitro translation platform to study the structure-activity relationship of ribosome-mediated antimicrobial resistance and drug safety	Marina Gysin, University of Zurich, Zurich, CH
29	Low cost, high throughput, in vivo screening of novel antimicrobials for efficacy and toxicity using TruLarv™ Galleria mellonella	Olivia L. Champion, BioSystems Technology, Exeter, UK
30	Microcalorimetry – a novel technique for rapid identification of synergistic antibiotic	Wilhelm Paulander, SymCel AB, Spånga, SE
31	Combinations for treatment of multidrug-resistant Gram-negative infections.	Mathias Winterhalter, Jacobs University, Bremen, DE
32	Modelling potentially virulence-associated metabolic pathways in Pseudomonas aeruginosa PA14 including experimental verification	Alina Renz, University of Tübingen, Tübingen, DE
33	A virtual screening method to predict permeation of molecules in Gram negative bacteria	Matteo Ceccarelli, University of Cagliari, Cagliari, IT
34	Machine learning workflow for efficient multiplexed antimicrobial resistance panel design	Andreas Posch, Ares Genetics GmbH, Vienna, AU
35	Sharing data in antimicrobial research (AMR): Simplifying descriptive metadata annotation	Manfred Kohler, Fraunhofer IME ScreeningPort, Hamburg, DE
36	Digging through the data: Computational tools to find novel anti-infectives	Nadine Ziemert, German Centre for Infection Research (DZIF), University of Tuebingen, Tuebingen, DE
37	Modeling the efficacy of compounds penetrating the membrane of Gram-negative bacteria	Susana Tomasio, Collaborative Drug Discovery, Cambridge, UK
<b>Diagnostics</b>		
38	Ultra-rapid identification and antimicrobial susceptibility evaluation directly from positive blood cultures	Rita Teixeira-Santos, FASTinov SA, Porto, PT
39	Validation of FASTinov® kits for ultrarapid AST directly from positive blood cultures	Ana Silva-Dias, FASTinov SA, Porto, PT
40	Advanced molecular diagnostics testing with CYCLE®	Lisa Dempfle, FRIZ Biochem GmbH, Neuried, DE
41	Rapid identification of carbapenem-resistant Acinetobacter baumannii with a novel immunochromatographic lateral flow assay	Sonja Mertins, University Hospital of Cologne, German Center for Infection Research (DZIF), Cologne, DE
42	Raman-dielectrophoresis chip for rapid antimicrobial susceptibility testing	Richard Grohs, Leibniz Institute of Photonic Technology, InfectedGnostics Research Campus, Jena, DE
43	Direct, specific and rapid detection of carbapenemases from culture material or in clinical samples using a multiplex antibody microarray	Elke Müller, Leibniz Institute of Photonic Technology, InfectedGnostics Research Campus, Jena, DE
<b>Other topics</b>		
44	Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread: Inference from a continent-wide population analysis	Sandra Reuter, University of Freiburg, Freiburg, DE
45	Transcontinental spread of MRSA clones	Stefan Monecke, Leibniz Institute of Photonic Technology (IPHT), InfectedGnostics Research Campus, Jena, DE
46	Genome based resistance prediction and outbreak analysis of Mycobacterium tuberculosis	Patrick Beckert, Research Center Borstel, Borstel, DE
47	Cell-free synthesis systems: A future platform technology for advanced screening of antimicrobial substances	Lena Thoring, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Potsdam, DE
48		sphingotec GmbH, Henningsdorf, DE



**LEIBNIZ**  
HEALTH  
TECHNOLOGIES

# **PREVENTION. DIAGNOSIS. THERAPY.**



## **POINT-OF-CARE TECHNOLOGIES**

Reliable diagnoses  
within minutes



## **IMAGING METHODS**

Fast detection and  
precise disease control



## **BIOMARKERS**

Objective parameters for  
successful individualized therapy




## **PLASMA MEDICINE**

Preventive care and  
personalized medical treatment



## **BIOACTIVE INTERFACES**

Functional materials for  
state-of-the-art medical technology



Symposium:

**PERSONALISIERTE MEDIZIN –  
DIAGNOSTIK – MEDIZINTECHNIK**  
20 March 2019 // Berlin



@LFV\_HealthTech

A Research  
Alliance  
of the

*Leibniz*  
Leibniz  
Association

# Sponsors and Exhibitors



## A&M Laboratory Group

Situated in the Heart of Europe the A&M Laboratory Group offers GxP compliant analytical services “Made in Germany”. With 250+ dedicated scientists and technicians, state-of-the-art equipment and a 25+ year flawless track record in authority and client audits, A&M is your analytical one-stop shop, supporting the development of your antimicrobial drugs

from development to manufacturing. With clients ranging from single person start-ups to big pharma we could be the ideal partner for your outsourcing needs, too.

[www.am-labor.de](http://www.am-labor.de)

## bioMérieux Pioneering diagnostics



As a major player in infectious disease diagnostics for over 55 years, bioMérieux has made the fight against antimicrobial resistance one of its core priorities. We offer a unique, comprehensive range of innovative diagnostic solutions that support the responsible use of antibiotics.

› Our high medical value diagnostic solutions iden-

tify multi-drug resistant bacteria, reduce antibiotic use by guiding appropriate therapy and track the spread of pathogens.

› We also develop educational resources to raise awareness of AMR and fund global surveys to monitor antibiotic use in hospitals.

[www.antimicrobial-resistance.biomerieux.com](http://www.antimicrobial-resistance.biomerieux.com)

## BOEHMERT & BOEHMERT

Intellectual property rights are our core competency



BOEHMERT & BOEHMERT

As one of the largest and best-known law firms for Intellectual Property (IP) in Europe, we offer our clients any and all services relating to IP. Our company is proficient with assisting clients with patents pertaining to technical inventions and the protection of designs and trademarks. We offer support in copyright, antitrust and competition law in all fields of

applied and engineering sciences. We have proven our expertise in traditional as well as young industries, and across borders.

[www.boehmert.com](http://www.boehmert.com)

## Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)



CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is investing \$500 million from 2016-2021 to support the development of innovative antibiotics, vaccines, rapid diagnostics

and other life-saving products, focusing exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is funded by the US Government (BARDA and NIAID), Wellcome Trust, the UK Government (GAMRIF) and the Bill & Melinda Gates Foundation. CARB-X headquarters are at Boston University School of Law.

[www.carb-x.org](http://www.carb-x.org)

# Sponsors and Exhibitors

## Collaborative Drug Discovery (CDD)



Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyse both biological study data and chemical structures, and to collaborate

with partners through a straightforward web-interface. CDD helps scientists register chemicals, track inventory, manage bioassay data, capture experiments on its Electronic Laboratory Notebook (ELN), calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. Learn more at [www.collaborativedrug.com](http://www.collaborativedrug.com)

## German Center for Infection Research (DZIF)



At the German Center for Infection Research (DZIF), about 500 researchers from 35 institutions throughout Germany jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim of this nationwide collaboration between universities, hospitals and research institutions is to translate research results into clinical

practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections. The DZIF is one of six German Centers for Health Research established by the Federal Ministry of Education and Research (BMBF) to combat the most common diseases. [www.dzif.de](http://www.dzif.de)

## FLANDERS INVESTMENT & TRADE

[www.investinlanders.com](http://www.investinlanders.com)



Flanders Investment and Trade is a government agency dedicated to assisting foreign companies that are considering developing their activity in Flanders - Belgium. Our goal is to facilitate, and the scope of our assistance is very broad, such as: organisation of a series of meetings with regional business leaders & sector influencers, information on the available workforce,

know-how and salaries, information on taxes, work regulations, social contributions in Flanders and Belgium, proposals for office, warehouse, storage, factory sites based on your specifications and many more. Our services are free of charge for foreign companies looking to set up business and we take care to exercise the level of confidentiality that you request.

## Global Antibiotic Research and Development Partnership (GARDP)



The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and

the Drugs for Neglected Disease initiative (DNDi), GARDP is an important element of WHO's Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage research and development of new antimicrobial agents and diagnostics.

[www.gardp.org](http://www.gardp.org)



## HEMEX

HEMEX, your dynamic consultancy partner and service provider



Our services involve the full range of **Regulatory, CMC, QA, Clinical Operations** and **Medical Affairs** expertise, needed to bring your product from the lab to the market. We offer hands-on consultancy and strategic mentoring to the life sciences industry with tailored solutions for start-ups. HEMEX's experts have several decades of combined experi-

ence in the life science industry and a history with the development of **anti-infectives and related diagnostic tests**. With our headquarters in Liestal, Switzerland and subsidiaries in Loerrach, Germany and Bethesda, USA, we offer **worldwide support** to our customers.

[www.hemex.eu](http://www.hemex.eu)

## InfectoGnostics



The InfectoGnostics research campus Jena is a public-private partnership developing new methods in infection diagnostics. In a triad of technology, application and production, more than 30 partners from science, medicine and industry are developing marketable solutions for rapid and cost-effective on-site analysis of infections (point-of-care testing) – such

as pneumonia (e.g. caused by antibiotic-resistant pathogens) in human medicine, animal diseases, and pathogen detection in food. The program is supported by its partners and the German ministry BMBF within the Research Campus initiative, an element of the High tech strategy.

[www.infectognostics.de](http://www.infectognostics.de)

## LEIBNIZ HEALTH TECHNOLOGIES:

A Research Alliance of the Leibniz Association



Providing technological solutions for unmet medical needs – this is the main focus of the 14 members of the interdisciplinary research alliance Leibniz Health Technologies.

To battle antimicrobial resistances, the Leibniz Institutes are cooperating in developing e.g. the "Ram-

anBioAssay", a photonics-based test to determine the efficacy of antibiotics (MIC) in less than 4 hours. The alliance is also inventing therapeutic devices based on cold atmospheric plasma, which is a suitable technology for deactivating various types of microorganisms, including multi-resistant bacteria such as MRSA.

[www.leibniz-healthtech.de](http://www.leibniz-healthtech.de)

## Microsynth



Microsynth (founded in 1989) is a leading European company in the area of nucleic acid synthesis & analysis. The main activities are divided into following three business areas:

1. DNA/RNA SYNTHESIS
2. DNA/RNA ANALYSIS AND SEQUENCING
3. CONTRACT RESEARCH/OUTSOURCING

For almost three decades, the company's objective has been to serve its customers by delivering products and services of the highest quality, on time and with outstanding service – and all this at competitive prices. Microsynth Seqlab is the German subsidiary of Microsynth AG and is located in Göttingen.

[www.microsynth.seqlab.de](http://www.microsynth.seqlab.de)

# Sponsors and Exhibitors

## Novo Holdings REPAIR Impact Fund



Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.

Novo Holdings manages ~EUR 50bn of assets on behalf of the Novo Nordisk Foundation. Novo Holdings invests exclusively in life science and actively supports more than 100 life science companies – from start-ups to well-established multinational companies. [www.repair-impact-fund.com](http://www.repair-impact-fund.com)

## Polyphor



Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing a novel class of Gram negative Antibiotics Targeting the Outer Membrane Proteins (OMPTA). The company's lead product, murepavadin, is in Phase III development against *Pseudomonas aeruginosa* – recognized as a critical priority 1 pathogen by WHO.

Murepavadin is also being developed as an inhaled version for Cystic Fibrosis and other lung diseases. Broad spectrum OMPTAs are in advanced preclinical stage with first compound planned to enter clinical development during 2020 (co-funded by Novo Repair Fund and Carb-X). Polyphor is listed on the SIX Swiss Exchange (SIX: POLN). [www.polyphor.com](http://www.polyphor.com)

## Resistell



Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The method is based on ground breaking invention from EPFL Lausanne - the detection of movement caused by living bacterial cells. Because the test is growth independent, we reduce the time

taken to get a result from days to minutes. Our mission is to provide the physicians with the diagnostic tool that will enable them to choose the most efficient but also most narrow spectrum antibiotic for the patient. We want to contribute to better treatment but also prevent spreading of AMR.

[www.resistell.com](http://www.resistell.com)

## sphingotec GmbH



sphingotec GmbH in Hennigsdorf, Germany, develops and markets the innovative biomarkers penKid® and bio-ADM® for the diagnosis, monitoring and therapy control of heart failure, acute kidney injury and septic shock, as well as and the Nexus IB10 POC platform, which was acquired in May 2018 with the acquisition of the Samsung subsidiary Nexus Dx

Inc. The product portfolio of the company, which was founded in 2002 by Dr. Andreas Bergmann, also includes biomarkers that help identify and prevent health risks before they manifest themselves, including obesity, cardiovascular diseases and breast cancer.

[www.sphingotec.com](http://www.sphingotec.com)

## The UK's Department for International Trade



The UK's Department for International Trade (DIT) is a specialist Government department that helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade.

DIT

➤ helps UK-based companies access overseas markets, providing confidential advice and support

necessary to assist you in achieving your export goals.

➤ helps overseas companies bring their high-level investment to the UK, providing professional, personalised and practical assistance and advice.

These services are offered through DIT's extensive network of sector & market specialists in offices all over the world.

[www.great.gov.uk](http://www.great.gov.uk)

## Supporting Partners

### BEAM Alliance



Since its inception in 2016, the BEAM (Biotech companies in Europe combating AntiMicrobial resistance) Alliance has succeeded in uniting European SMEs involved in the discovery and development of novel antimicrobial therapies and diagnostics. The BEAM Alliance is a unique contributor to help our understanding of the complex array of cross-disciplinary

issues mixing science, finance and policymaking. By collaborating with the existing community of global stakeholders, the BEAM Alliance is giving its members a unique voice to recommend bold incentives fitting the needs of SMEs, the driving force of today's innovation in the field.

[www.beam-alliance.eu](http://www.beam-alliance.eu)

### European Biotechnology Network



The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. It has members in all European countries and beyond. As a non-profit organisation the European Biotechnology Network AISBL is registered in Belgium. Since 2007, the constantly growing network

has brought research groups, universities, SMEs, large companies and indeed all actors in biotechnology together.

[www.european-biotechnology.net](http://www.european-biotechnology.net)

### ND4BB ENABLE



Within IMI's ND4BB programme, ENABLE (European Gram-negative antibacterial engine) has a €85 million budget to develop compounds active against Gram-negative bacteria. The heart of the project is a drug discovery platform for testing and optimising compounds from hit phase through preclinical phases. ENABLE provides funding for European SMEs and

research groups to progress promising programmes up to clinical phase I. ENABLE has the goal to develop at least one phase II-ready compound as well as a pipeline of attractive antimicrobial candidates for FIH clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.

[www.nd4bb-enable.eu](http://www.nd4bb-enable.eu)



# Media Partners

## BioPartner



BioPartner UK is the accredited trade organisation that provides practical support and international promotion to UK Life Sciences companies, who wish to grow their business overseas. BioPartner signposts to UK expertise and leads delegations to promote the UK presence at major international biopharma conferences. By operating in partnership with the

UK government and event organisers, BioPartner assists all UK companies with access to government grants and heavily discounted entry fees. Members of the BioPartner Programme receive extra benefits and support to effectively trade overseas.

[www.biopartner.co.uk](http://www.biopartner.co.uk)

## European Biotechnology Life Sciences & Industry Magazine



For almost two decades, the European Biotechnology Life Sciences & Industry Magazine has been covering the scientific, political and economic development of biotechnology and life sciences in the 28 countries of the European Union as well as in

Switzerland and Norway. With a circulation of more than 13,000 copies, the European Biotechnology Magazine is the leading European specialist journal for life sciences. Daily news is available online at

[www.european-biotechnology.com](http://www.european-biotechnology.com)

# Investor Meeting Partners



# Engage with customers all over Europe.

Europe is a common research area and for the industry, it represents a huge unified market with 526 million potential customers. The magazine European Biotechnology has been both monitoring and shaping this economic area for 18 years now. Together, we can keep improving. Join us!

Annual subscription 80€.  
Please order online:  
[european-biotechnology.com](http://european-biotechnology.com)




# European Gram-negative Antibacterial Engine

ENABLE is a fully functional drug development platform that provides non-dilutive funding for European SMEs and research groups to work in collaboration with partners to progress anti-infective Gram-negative compounds and bring them into clinical trials. It is a public-private partnership collaboration in which EFPIA companies, SMEs, academia and independent experts join forces.

To date, ENABLE has received 101 Expressions of Interest (EoIs) and has supported 22 programmes. 64 EoIs were submitted by SMEs, 33 EoIs came from academia and 4 EoIs from large pharma companies. Overall, these EoIs reached ENABLE from 20 different countries.

## THE ENABLE ENGINE



## REACHING GOALS FOR 2020

	Lead compound	Drug candidate	Clinical phase 1
<b>Ambition</b>	3 lead compounds	2 drug candidates	1 antibiotic in phase 1
<b>Interim status</b>	5 lead compounds	1 selected	1 in prep. for phase 1

>>> Get in touch now to find out more:

**[www.nd4bb-enable.eu](http://www.nd4bb-enable.eu)**

# Participants

Name	Surname	Position	Company	CC
Marit	Ackermann	Referentin	Bundesministerium für Bildung und Forschung	D
Uwe	Albrecht	CEO	Mediconomics GmbH	D
Sofia	Almqvist	R&D Manager Bioactive Research	Mölnlycke	S
Silke	Alt		Deutsches Zentrum für Infektionsforschung e.V. (DZIF)	D
Dario	Ambrosini	Research Scientist	AGILeBiotics BV	NL
Anand	Anandkumar	CEO	BUGWORKS Research India Pvt. Ltd.	IND
Frank	Apostel	Vice President, Business Development Companion Diagnostics		D
Sven	Arnouts	Business Developer	PROVAXS - University of Ghent	B
Marie	Asano	Investment Manager	High-Tech Gründerfonds Management GmbH	D
Matthias	Bach	Projektmanager Marketing	BIO Deutschland e.V.	D
Till	Bachmann	Deputy Head of Division of Infection and Pathway Medicine	University of Edinburgh	GB
Niv	Bachnoff	CSO	Omnix Medical	IL
Seweryn	Bajer-Borstyn		Scope Fluidics S.A.	PL
Renate	Baker	Europe Account Manager	Collaborative Drug Discovery	GB
Clara	Ballesté Delpierre	Coordinator of the Antimicrobial Resistance Initiative	Barcelona Institute for Global Health (IS Global)	E
Özden	Baltekin	Chief Scientific Officer	Astrego Diagnostics AB	S
Enrico	Baraldi	Professor of Industrial Engineering & Management	Uppsala University	S
Andreas A.	Bastian	CEO	AGILeBiotics B.V.	NL
Maria	Bastian	CSO	AGILeBiotics B.V.	NL
Patrick	Beckert	Doctoral student	Research Center Borstel	D
Els	Beirnaert	CEO	Aelin Therapeutics	NL
Alexander	Belcredi	Co-Founder   CEO	PhagoMed Biopharma GmbH	A
Mikkel	Bender	CFO	BKG Pharma	DK
Torbjörn	Bengtsson		Curenc.AB	S
Andreas	Bergmann	CEO	sphingotec GmbH	D
Deborah	Bergmann	Vice President Marketing	sphingotec GmbH	D
Daniel	Berman	Global Health Team Lead, Challenge Prize Centre	NESTA	GB
Charlotte	Bermingham	Chief Technology Officer	Vitamica	GB
Thierry	Bernardi	CEO	BioFilm Pharma	F
Hubert S.	Bernauer	CEO	ATG:biosynthetics GmbH	D
Peter	Beyer	Senior Advisor Department of Essential Medicines & Health Products	World Health Organization (WHO)	CH
Michael	Böhringer		Friedrich-Loeffler-Institut	D
Katja	Bölcker	Project Manager, ENABLE	BIOCOM AG	D
Jessica	Boname	Programme Manager for AMR	Medical Research Council (UK)	GB
Abdelhakim	Boudrioua	PhD student	Université de Caen Normandie	F
Sascha	Braun	Scientist	InfectoGnostics Forschungscampus Jena e.V.	D
Coen	Breedveld	Co-Founder	Levels Diagnostics	NL
Michael	Burnet	Managing Director	Synovo GmbH	D
Esteban	Burrone	Head of Policy	Medicines Patent Pool	CH
Jonathan	Butcher	Head Business Development and Alliance Management	BioVersys	CH
Martin	Caffrey	Professor	Trinity College Dublin	IRL
James	Cass	Research Manager	Phico Therapeutics Ltd	GB

Name	Surname	Position	Company	CC
Matteo	Ceccarelli	Associate Professor	University of Cagliari	I
Olivia	Champion	CEO	BioSystems Technology	GB
Uzma	Choudry	VC Investor	Octopus Investments	GB
Francesco	Ciabuschi	Professor at Department of Business Studies	Uppsala universitet	S
Danuta	Cichocka	CEO	Resistell AG	CH
Moshik	Cohen-Kutner	CEO	Omnix Medical	IL
Daniele	Colombo	Search & Evaluation Manager	Zambon SpA	I
David	Corcoran	Co-founder	CC Bio	GB
Edward	Cox	Director	U.S. Food and Drug Administration	US
Marc	Creus	Group Leader	University of Basel	CH
Matthew	Cummings	Co-founder	CC Bio	GB
Pedro Henrique	D. Batista		Max Planck Institute for Innovation and Competition	D
Glenn	Dale	Chief Development Officer	BioVersys	CH
Michel	de Baar	Executive Director	MSD	GB
Leonie	de Best	CBO	Madam Therapeutics BV	NL
Kees	de Joncheere		NADP Netherlands Antibiotic Development Platform	NL
Sebastian	Delbrück	Consultant	VDI/VDE-IT GmbH	D
Robert	DeLuccia	Cofounder & Managing Partner	Acurx Pharmaceuticals	US
Lisa	Dempfle		FRIZ Biochem GmbH	D
Colin	Denver	CEO	SpeeDx	AUS
Lindsay	Derek	COO	AMR Centre Ltd	GB
Frederik	Deroose	CEO	Asclepia	B
Charles-Henry	DION	Strategic Partnership Manager – Anti-Microbials	BIOASTER	F
Graham	Dixon	CEO	Neem Biotech	GB
Christian	Döring	Wissenschaftskommunikation	Forschungsverbund Leibniz Gesundheitstechnologie	D
Ralf	Dümpelmann	Senior Project Manager	BaselArea.swiss	CH
Atila	Durmus	Sales Manager Germany and Austria	Microsynth AG	CH
Christopher	Egerton-Warburton	Co-CEO	Lion's Head Global Partners	GB
Ralf	Ehricht	Group Leader	InfectoGnostics Forschungscampus Jena e.V.	D
Amit	Elbaz	CEO	Life Matters	IL
Aleks	Engel	Director Principal Investment	Novo Holdings A/S	DK
Mark	Engel	CEO	Phagelux	VRC
Markus	Engelhard	European Patent and Trademark Attorney	Boehmert & Boehmert	D
Jesper	Ericsson	CEO	Symcel	S
Lucia	Erroba	Head of Business Development	Ikan Biotech	E
Martin	Everett	CSO	ANTABIO SAS	F
Heather	Fairhead	CEO	Phico Therapeutics Ltd	GB
Rüdiger	Falke	Teacher for sciences		D
Cecilia	Ferreyra	AMR Medical Officer	FIND	CH
Yann	Ferrisse	BC Head	GARDP Foundation	CH
Christian	Fetzer		aBACTER - TUM	D
James David	Findlay		Morton Findlay Associates Ltd	GB
Laurent	Fraisse	Executive Vice President	Evotec ID (Lyon) SAS	F
Sara	Frojdo	Strategic Partnership Manager – Diagnostics	BIOASTER	F
Miriam	Fürst-Wilmes	Scientist	Federal Institute for Drugs and Medical Devices (BfArM)	D
Thomas	Gabrielczyk	Editor	European Biotechnology Magazine	D
Karen	Gallant	CARB-X Global R&D Project Director	CARB-X	US



Name	Surname	Position	Company	CC
Piotr	Garstecki	Board Member	Bacteromic sp. z o.o.	PL
Corinne	Geissler	Portfolio Manager Bacteriology	Evotec	F
Olga	Genilloud	Scientific Director	Fundación MEDINA	E
Sina	Gerbach	Management Drug Development, Scientific Coordinator	Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (HKI)	D
Erik	Gerner	PhD Student	University of Gothenburg	S
Marc	Gitzinger	CEO	BioVersys AG	CH
Andrew	Goldman	Associate Counsel	Medicines Patent Pool	CH
Grzegorz	Gonciarz	Partner	Resistell	CH
Tomasz	Gondek	President of the Board	SensDx SA	PL
Victoria	Goodfellow	Executive Director	Lion's Head Global Partners	GB
Lasse H.	Görlitz	Director of Communications	grit42	DK
Martin	Griessl	Deputy Director R&D, Head of Protein Design	Lisando GmbH	D
Richard	Grohs	Doctoral Student	CSCC	D
Ibrahima	Guillard	Account Manager	Mutabilis	F
Marina	Gysin	Scientific Associate	University of Zurich	CH
Mathias	Hackl		aBACTER - TUM	D
Lars Ole	Haustedt	Director Projects & Innovation	AnalytiCon Discovery GmbH	D
Markus	Heep	Clinical Scientific Expert	Amplex	D
Sabina	Heim	Senior Technology Manager	Ascenion GmbH	D
Frauke	Hein	Chief Business Officer	AdrenoMed AG	D
Jens	Hellwage	CEO	InfectoGnostics Forschungscampus Jena e.V.	D
Daland C.	Herrmann	Scientist	Indical Bioscience GmbH	D
Katja	Herzog	European Relations and Grant Officer	EU-OPENSOURCE ERIC	D
Thomas	Hestekamp	Head Translational Project Management	German Center for Infection Research, Helmholtz Centre for Infection Research	D
Sven	Hobbie	CEO	Juvabis GmbH	CH
Achim	Hoerauf	Institutsleiter	Rheinische Friedrich-Wilhelms-Universität Bonn	D
Michael	Hogrebe		sphingotec GmbH	D
Ruby	Holder	Vice President, Investments	Roivant Pharma	US
Hans Christian	Holländer	Senior Business Developer	Technical University of Denmark	DK
Uta	Holmer	Event Management	BIOCOM AG	D
Jennie	Hood	Scientific Programme Officer	Global AMR R&D Hub	D
Chris	Howie	Life Science Specialist – Europe	Department for International Trade	GB
Melody	Huang	Marketing Manager Europe	Celerion	D
Irene	Huber	Managing Director	Uni Hohenheim	D
Diarmaid	Hughes		Uppsala University	S
Christin	Human		Deutsches Zentrum für Infektionsforschung e.V. (DZIF)	D
Bogdan	Iorga		CNRS-ICSN	F
Peter	Jackson	Executive Director	AMR Centre Ltd	GB
Timo	Jäger	Managing Director	German Center for Infection Research – DZIF	D
Magnus	Jansson	CSO	Symcel	S
Angie	Jarrad	Postdoctoral Fellow	Helmholtz Centre for Infection	D
Dušan	Jasovský	AMR/Regulatory Pharmacist	Doctors Without Borders	CH
Anna	Jedrusik		EFPIA	B
Timothy	Jinks	Head of Drug Resistant Infections Programme	Wellcome Trust	GB
Mark	Jones	Head of Project Management and Head of PreClinical Development	Basilea Pharmaceutica Ltd.	CH
Gabriela	Juarez Martinez	Knowledge Transfer Manager – Pharma and Medtech	Knowledge Transfer Network	GB
Françoise	Jung	Business Development Manager	Polyphor AG	CH



Name	Surname	Position	Company	CC
Frank	Kalkbrenner	Vice President Boehringer Ingelheim Venture Fund	Boehringer Ingelheim Venture Fund GmbH	D
Jerzy	Karczewski		Fraunhofer USA	US
Jennifer	Katz	Head of Development	GARDP Foundation	CH
Senait	Kebede	Associate Professor (Adjunct)	Emory University	US
Paul	Kennouche	Wissenschaftsreferent für Gesundheit, Medizin, Pharmakologie und Bioethik	Französische Botschaft	D
Christian	Kern		Microsynth AG	CH
Helmut	Kessmann	Head Business Development	Polyphor Ltd	CH
Hazem	Khalaf	Associate Professor, CSO	Curenc.AB	D
Ute	Kilger	Patentanwältin – European Patent and Trademark Attorney	Boehmert & Boehmert	D
Tobias	Klaassen	Laboratory Head / Study Director GLP	A&M Labor GmbH	D
Ina	Klaus	Leiterin Projektgruppe „Pharmadialog“	Bundesministerium für Gesundheit	D
Alexander	Klimka	PI	University Hospital Cologne	D
Daniel	Knappe	Director Peptide Therapeutics	EnBiotix GmbH	D
Jeremy	Knox		Wellcome Trust	GB
Paul	Ko Ferrigno	CEO	metaLinear Ltd	GB
Manfred	Kohler	Scientific Solution Development	Fraunhofer IME ScreeningPort	D
Dagmar	Köhler-Repp	Geschäftsführerin	RIPAC-LABOR GmbH	D
Axel	Kölling	Medical Director Germany	Shionogi GmbH	D
Gergely	Krajcsi	Investment Officer, Growth Capital & Innovation Finance	European Investment Bank	L
Kathrin	Landgrebe	Projectmanager	Berlin Partner for Business and Technology	D
Francesco	Lanza	Research Scientist	AGLeBiotics BV	NL
Martin	Laqua	Editor	ltranskript	D
Alice	Law	Research Associate	University of Liverpool	GB
Richard	Lawson	Senior Project Manager	CARB-X	US
Matthias	Lehmann	Geschäftsführung	8sens.biognostic GmbH	D
Marc	Lemonnier	CEO	ANTABIO SAS	F
Colm	Leonard	Consultant Clinical Adviser	National Institute for Health and Care Excellence (NICE)	GB
Lisette	Leonhardt		VDI/VDE Innovation + Technik GmbH	D
Markus G.	Leyck Dieken	Country Manager Germany	Shionogi GmbH	D
Andrew	Lightfoot	CEO	Procarta Biosystems	GB
Pedro	Madureira	CSO	Immunetep SA	P
Christer	Malmberg	Lead Development Engineer	Gradientech AB	S
Rohit	Malpani		ReAct	S
Franziska	Mandl	Project Head aBACTER	Technical University of Munich	D
Boris	Mannhardt	CEO	BIOCOM AG	D
Jessica	Manthey	Investment Promotion Manager	Flanders Invest & Trade	D
Fiona	Marston	Director	Centre of Excellence in Infectious Diseases Research (CEIDR)	GB
Clive	Mason	Senior Director, Platform Discovery	Summit Therapeutics	GB
Egill	Másson	CEO	Akthelia Pharmaceuticals	IS
James	McIlroy	Founder and President	EnteroBiotix	GB
Paul	Meo	Associate Director, Anti-infective Research	Summit Therapeutics	GB
Katja	Mertens-Scholz		Friedrich-Loeffler-Institut	D
Sonja	Mertins	Postdoc	University Hospital Cologne	D
Robin	Michelet	Post-doctoral researcher	Freie Universitaet Berlin	D
Iain	Miller	CEO	SAW Dx	GB
Nivedita	Mitra	Key Expert	Siemens Healthineers	IND
Tom	Monroe	CEO	Vaxxilon	CH

Name	Surname	Position	Company	CC
Maria	Morales		Ikan Biotech	E
Javier	Moreno Morales	PhD student	ISGlobal	E
Michael	Mourez	Platform Head	Evotec	F
Magdalini	Moutafsi	Scientific Programme Officer	Global AMR R&D Hub	D
Nathalia	Murillo	Alliance Manager	Evotec	F
Amani	Musa		Örebro Univeristy	S
Kakha	Nadiradze	President	Association for Farmers Rights Defense (AFRD)	GEO
Sumathi	Nambiar	Director, Division of Anti-Infective Products (DAIP), Office of Antimicrobial Products	FDA	US
Ika	Narwidya	Policy Analyst	The Cabinet Secretariat of the Republic of Indonesia	RI
Peter	Neubeck	Partner	Kurma Partners SA	D
Cristina	Niculescu		European Investment Bank	L
Elmar	Nimmesgern	Secretariat Lead	Global AMR R&D Hub	D
Julia	Nolte-Rostami	Science and Innovation Officer	UK Science & Innovation Network	D
Katharina	Nothelfer	Senior Manager Grants	AiCuris Anti-infective Cures GmbH	D
Seamus	O'Brien	R&D Director	Global Antibiotic R&D Partnership (GARDP)	CH
Raymond	Okechukwu	Assistant Director of Pharmacy	Nnamdi Azikiwe University Teaching Hospital Nnewi	NGR
António	Ornelas Soares	Executive Board Member, Strategic Alliances	FASTinov	P
Dave	Ousterout	CTO	Locus Biosciences	US
Kevin	Outterson	Executive Director	CARB-X	US
Jean-Pierre	Paccaud	Dir. BD & Corporate Strategy	GARDP Foundation	CH
Phil	Packer	Innovation Lead: AMR and Vaccines	Ageing Society, Health & Nutrition Innovate UK	GB
Malcolm	Page	Director	Malcolm Page GmbH	CH
Katarzyna	Pala	Business Development Director	SensDx SA	PL
Ricardo	Palacios	BD Manager – In vivo Sales Specialist	Eurofins CEREP SA	F
Christophe	Parsy	Pharmaceutical Program Director	Deinove SA	F
Wilhelm	Paulander	BD Manager	Symcel	S
Sarah	Paulin	Technical Officer	World Health Organization	CH
Lloyd	Payne	Member of fund SAB	Evotec	GB
Jonathan	Pearce	Head of Infections & Immunity	JPI AMR & Medical Research Council	GB
Claney	Pereira	Managing Director and Director of Chemistry	Vaxxilon Deutschland GmbH	D
Marie	Petit	BEAM Coordinator	Villiger Valuation – Bout d'Ouchée Sàrl	CH
Frédéric	Peyrane		BEAM Alliance	F
Kenneth	Pfarr	Group Leader	University Hospital Bonn	D
Dieter	Pfeifle	Business Development Manager Lifescience	RKT Rodinger Kunststoff-Technik GmbH	D
Aldona-Maria	Pigozzo	Marketing & Kommunikation	Bosch Healthcare Solutions GmbH	D
Cidália	Pina-Vaz	CEO & Co-founder	FASTinov	P
Achim	Plum	COO	Curetis N.V.	D
Andreas	Posch	Managing Director	Ares Genetics	A
Prajwal	Prajwal		Clemedi	CH
Udi	Qimron	Sensitizing pathogens to antibiotics using the CRISPR-Cas system	Tel Aviv University	IL
Wandrille	Ract-Madoux	Director	Mutabilis	F
Alina	Renz		University of Tübingen	D
Sandra	Reuter		UNIVERSITÄTSKLINIKUM FREIBURG	D
John	Rex	CMO	F2G Ltd.	US
William	Rhys-Williams	Projects Director	Destiny Pharma plc	GB
Rosemarie	Riedl	Sen.Dir. Medicinal Chemistry	Nabriva Therapeutics GmbH	A
Christian	Riemann	CEO	Global Investment Bridge AG und Bacterio-bator	D

Name	Surname	Position	Company	CC
Christine	Rohde		Leibniz-Institut DSMZ GmbH	D
Antje	Rötger	CEO	Carpegen GmbH	D
Annika	Rudat	Senior Manager Events	BIOCOM AG	D
Szymon	Ruta	CFO	Scope Fluidics S.A.	PL
Izabela	Sabala	PL	International Institute of Molecular and Cell Biology in Warsaw	PL
Muhammad	Salman	Assistant Professor	Abasyn University Peshawar	PK
Bruno	Santos	CEO	Immunetep SA	P
Karine	Santos		sphingotec GmbH	D
Lukas	Schablauer	CFO	Mediconmics GmbH	D
Andrea	Schiefer	PostDoc	University Hospital Bonn	D
Ansgar	Schmidt-Bleker		Leibniz Institute for Plasma Science and Technology	D
Holger	Schmoll	CFO	AiCuris Anti-infective Cures GmbH	D
Jennifer	Schneider		Centauri Therapeutics Ltd	GB
Oliver	Schnell	Head of Marketing	BIOCOM AG	D
Matthias	Scholz	Senior Scientist, PI	University of Bonn	D
Timothy	Schulz-Utermoehl	Co-Founder and Director	Pedanius Therapeutics	GB
Reinier	Schwietert	CEO	PureIMS B.V.	NL
Alexandra	Seifert	Director, Business Development	Celerion	D
Florence	Séjourné	CEO	Da Volterra	F
Michael	Silverman	Medical Director	Acurx Pharmaceuticals. LLC	US
Jean-Claude	Sirard	Research Director	INSERM	F
Robert	Skov	Lead of ICARS Project Team & National AMR coordinator	Statens Serum Institut	DK
Jan	Skriwanek		Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR)	D
Christoph	Spennemann	Legal Officer and Officer-in-Charge	UNCTAD	CH
Marina	Steindorff		Helmholtz-Zentrum für Infektionsforschung	D
Claus	Stie Kallesøe	CEO & Co-founder	grit42	DK
Frank	Surup	Scientist	Helmholtz Centre for Infection Research	D
Shahida	Syed	Research Project Coordinator	Department of Health and Social Care	GB
Pierre	Tangermann	Head of BD and Marketing	Fraunhofer IZI-BB	D
Lukas B.	Tanner	Business Development Manager	Nemis Technologies AG	CH
Nicolas	Tesse	R&D	SEPTEOS	F
Ursula	Theuretzbacher	Geschäftsführer	Center for Anti-Infective Agents	A
Gwynneth	Thomas	Investment Manager	Stonehaven Incubate AG	CH
Lena	Thoring	PostDoc	„Fraunhofer Institute for Cell Therapy and Immunology (IZI) Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam Department of Cell-free Bioproduction“	D
Sara	Thorslund	CEO	Gradientech	S
Susana	Tomásio	Senior Application Scientist	Collaborative Drug Discovery	GB
Keiko	Tone	VP Global Market Access	Shionogi Limited	GB
Diego	Tonelli		European Investment Bank	L
Didem	Torumkuney	Scientific Director – Global SOAR Lead Infectious Diseases	GlaxoSmithKline	GB
Lars	Ullrich	Managing Director Business Development	GNA Biosolutions GmbH	D
Mathew	Upton	CSO	Amprologix	GB
Alex	van Belkum	R&D Director	bioMérieux	F
Maarten	van Dongen	Director	AMR INSIGHTS	NL

<b>Name</b>	<b>Surname</b>	<b>Position</b>	<b>Company</b>	<b>CC</b>
Helmuth	van Es	Chief Business Officer	ANTABIO SAS	F
Remko	van Leeuwen	CEO	Madam Therapeutics BV	NL
Jan	van Üüm	Scientific Officer	DLR Project Management Agency	D
Mariana	Vaschetto	Operations Head, EMEA and LATAM	Collaborative Drug Discovery	GB
Philippe	Villain-Guillot	CEO	Nosopharm SAS	F
Manuel	Villegas Caballero	Senior Risk Modeller	Swiss Re	CH
Nicole	von Allmen	Project Leader	Labor Berlin	D
Cuong	Vuong	Director, Research Bacteriology	AiCuris Anti-infective Cures GmbH	D
Steven	Watt	Business Development	A&M Labor GmbH	D
Christin	Weber	Referentin	InfectoGnostics Forschungscampus Jena e.V.	D
Jörg	Weber		Biophotonics Diagnostics GmbH	D
Erica	Westwood	Project Lead	Department of Health & Social Care	GB
Urs	Widmer	Senior Medical Officer	Swiss Re	CH
Joanna	Wiecek	Science Officer	Wellcome Trust	GB
Adrian	Wildfire	Scientific Director	SGS Belgium NV	B
Stephan	Wildner	Business Development Manager - Clinical Research	SGS Belgium NV	B
Klaus	Wilgenbus	CEO	Allegra Therapeutics GmbH	D
Laurie	Williams	Business Development Manager	„Department for International Trade British Consulate General“	D
Oliver	Williams	Policy Officer	Wellcome Trust	GB
Björn	Windshügel	Head of Structure-Based Drug Design	Fraunhofer IME	D
Pascal	Winnen	CEO	HEMEX AG	CH
Tobias	Winter		UNIQA Capital Markets GmbH	A
Mathias	Winterhalter	Professor	Jacobs University Bremen gGmbH	D
Sandra	Wirsching	Managing Editor	BIOCOM AG	D
Britta	Wlotzka	Project Manager	Landesentwicklungsgesellschaft Thüringen mbH	D
Richard	Zahl	Life Science Business Associate	Ares Genetics	A
Adam	Zerda	Director, AMR Strategy and Development	Becton Dickinson	US
Ghada	Zoubiane	Science Lead, Drug-Resistant Infections	Wellcome Trust	GB
Déborah	Zyss	Senior Scientific officer	AGENCE NATIONALE DE LA RECHERCHE	F

# Notes

## Imprint

### PUBLISHER & PRODUCTION

BIOCOM AG

Lützowstraße 33–36

10785 Berlin, Germany

[www.biocom.de](http://www.biocom.de)

### EDITORIAL TEAM

Sandra Wirsching (Editor)

Annika Rudat, Uta Holmer, Katja Bölcker (Event team)

Michaela Reblin (Design)

Benjamin Röbig (Production)

### PRINT OFFICE

H. Heenemann, Berlin

### PHOTO CREDITS

Title: ©Sebastian Kaulitzki/stock.adobe.com

This brochure accompanies the “Novel Antimicrobials and Diagnostics 2019” conference, taking place from 14 to 15 March in Berlin, Germany. All profiles and contents related to organizations, networks or companies was provided externally. No responsibility is taken for the correctness of this information.

[www.amr-conference.com](http://www.amr-conference.com)



See you again next year!

Mar 12|13  
**2020**

[amr-conference.com](https://amr-conference.com)  
**#AMRconference**